Crizotinib, which is regarded as the first-line treatment for stage IV NSCLC patients with ALK gene rearrangements according to the clinical practice guidelines given by the American Society of Clinical Oncology (ASCO) (4), has a proven therapeutical efficacy. The gene discussed is ALK; the disease is non-small cell lung carcinoma.